NCT06666010View on ClinicalTrials.gov

PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

July 31, 2028

Conditions
Stimulant Use Disorder
Interventions
DRUG

PEX010-Assisted Therapy

The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.

DRUG

PEX010(01)

The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.

Sponsors
All Listed Sponsors
collaborator

University of British Columbia

OTHER

lead

Filament Health Corp.

INDUSTRY